[Not all antihypertensive agents protect equally well].
D000179:Acrylates / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007093:Imidazoles / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D009568:Nitrendipine / Q000627:therapeutic use; D011322:Primary Prevention; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use; D013997:Time Factors
D000179:Acrylates; D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan; D009568:Nitrendipine